Israel Englander Fusion Pharmaceuticals Inc. Transaction History

Millennium Management LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$7.9 - $21.32 $8.14 Million - $22 Million	1,030,780 Added 178.3%	1,608,882 $34.3 Million
Q4 2023 Feb 14, 2024	BUY	$2.48 - $9.65 $603,942 - $2.35 Million	243,525 Added 72.79%	578,102 $5.56 Million
Q2 2023 Aug 14, 2023	SELL	$3.47 - $5.33 $240,162 - $368,894	-69,211 Reduced 17.14%	334,577 $1.56 Million
Q1 2023 May 15, 2023	BUY	$3.03 - $5.13 $1.22 Million - $2.07 Million	403,788 New	403,788 $1.47 Million
Q2 2022 Aug 15, 2022	BUY	$2.49 - $7.86 $29,187 - $92,134	11,722 New	11,722 $29,000
Q4 2021 Feb 14, 2022	SELL	$4.17 - $7.78 $112,277 - $209,476	-26,925 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$7.83 - $9.41 $210,822 - $253,364	26,925 New	26,925 $213,000
Q2 2021 Aug 16, 2021	SELL	$7.97 - $10.66 $85,486 - $114,339	-10,726 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$9.75 - $13.09 $348,894 - $468,412	-35,784 Reduced 76.94%	10,726 $115,000
Q4 2020 Feb 16, 2021	SELL	$11.5 - $13.73 $1.57 Million - $1.87 Million	-136,202 Reduced 74.54%	46,510 $546,000
Q3 2020 Nov 16, 2020	SELL	$11.8 - $17.1 $327,910 - $475,191	-27,789 Reduced 13.2%	182,712 $2.2 Million
Q2 2020 Aug 14, 2020	BUY	$17.0 - $17.78 $3.58 Million - $3.74 Million	210,501 New	210,501 $3.68 Million

93K

1.4K

Ticker FUSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,390,500
Description
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order ...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.